CagriSema (Cagrilintide + Semaglutide): The Next-Generation Weight Loss Combo Explained

A new era in obesity medicine is taking shape. CagriSema — a once-weekly injectable combination of cagrilintide and semaglutide — has emerged from Novo Nordisk's pipeline as one of the most anticipated weight-loss therapies in a generation. With phase 3 trial data showing average body weight reductions of more than 20%, and an FDA New Drug Application filed in December 2025, CagriSema could redefine what patients and clinicians expect from pharmacological weight management.

This guide covers everything you need to know: how CagriSema works, what the clinical evidence shows, how it compares to semaglutide and tirzepatide, and what the road to FDA approval looks like.

What Is CagriSema?

CagriSema is a fixed-dose combination of two distinct compounds:

• Semaglutide 2.4 mg — a glucagon-like peptide-1 (GLP-1) receptor agonist, the same active ingredient found in Wegovy and Ozempic
• Cagrilintide 2.4 mg — a novel long-acting analogue of amylin, a pancreatic hormone that works alongside insulin to regulate appetite and blood sugar

Both components are administered as a single subcutaneous injection once per week. If approved, CagriSema would represent the first-ever combination of a GLP-1 receptor agonist and an amylin analogue in a single treatment — a genuinely new pharmacological class.

How Does CagriSema Work? Dual Mechanism of Action

The scientific rationale for combining these two agents is compelling. Semaglutide and cagrilintide act on different but complementary pathways, producing a synergistic effect on appetite, satiety, and metabolic regulation.

Semaglutide: The GLP-1 Component

GLP-1 is an incretin hormone released from the gut after eating. Semaglutide mimics GLP-1 effects by:

• Activating GLP-1 receptors in the hypothalamus and brainstem, reducing hunger signals
• Slowing gastric emptying, prolonging feelings of fullness after meals
• Stimulating insulin secretion while suppressing glucagon, improving blood glucose control
• Acting on reward pathways in the brain to reduce food cravings

Semaglutide's half-life has been extended to approximately one week through lipidation and albumin binding, enabling once-weekly dosing.

Cagrilintide: The Amylin Component

Amylin is a 37-amino acid peptide co-secreted with insulin from the beta cells of the pancreas. In people with obesity or type 2 diabetes, amylin signaling is often impaired. Cagrilintide restores and amplifies that signal by:

• Binding to amylin receptors (AMYR1 and AMYR3) in the hypothalamus and area postrema, suppressing appetite via central satiety circuits
• Slowing gastric emptying through vagal pathways, extending post-meal fullness
• Suppressing post-prandial glucagon, reducing glucose excursions after meals
• Influencing hedonic eating behavior independently of GLP-1 pathways

Cagrilintide was engineered through lipidation and amino acid modifications to extend native amylin's half-life from minutes to approximately 7 days, making once-weekly dosing feasible.

Why Combining Both Makes Scientific Sense

GLP-1 and amylin act on overlapping but distinct neural circuits. GLP-1 receptor agonists primarily reduce appetite through hypothalamic signaling, while amylin acts more prominently on the brainstem area postrema and via vagal afferents. By engaging both pathways simultaneously, CagriSema achieves a more comprehensive suppression of hunger and caloric intake than either agent alone — a principle the clinical trials have validated.

The REDEFINE Clinical Trials: Key Results

CagriSema has been evaluated in the REDEFINE program, a series of phase 3a trials. The pivotal trials — REDEFINE 1 and REDEFINE 2 — were published simultaneously in The New England Journal of Medicine in June 2025 and presented at the American Diabetes Association Scientific Sessions.

REDEFINE 1: Adults Without Type 2 Diabetes

REDEFINE 1 enrolled 3,417 adults with obesity (BMI ≥30 kg/m²) or overweight with at least one complication (BMI ≥27 kg/m²), without type 2 diabetes. Participants were randomized to CagriSema 2.4/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo — all once weekly for 68 weeks, alongside lifestyle interventions.

Key results at week 68:

• CagriSema: −20.4% to −23% mean body weight reduction (vs −3.0% with placebo)
• Semaglutide alone: −16.1% mean body weight reduction
• Cagrilintide alone: −11.8% mean body weight reduction
• ≥5% weight loss achieved: 91.9% of CagriSema participants (vs 31.5% with placebo)
• ≥20% weight loss achieved: 60% of CagriSema participants
• ≥30% weight loss achieved: 23% of CagriSema participants

The combination's ~7 percentage point advantage over semaglutide monotherapy is clinically meaningful and supports the dual-mechanism rationale.

REDEFINE 2: Adults With Type 2 Diabetes

REDEFINE 2 enrolled 1,206 patients with obesity or overweight and type 2 diabetes, randomized to CagriSema or placebo for 68 weeks.

Key results:

• CagriSema: −13.7% mean body weight reduction (vs −3.4% with placebo)
• HbA1c reduction: −1.91% with CagriSema — a significant improvement in glycemic control

Weight loss was modestly lower in the T2D population, consistent with patterns seen for semaglutide and tirzepatide.

REDEFINE 4: Head-to-Head Against Tirzepatide

REDEFINE 4 directly compared CagriSema to tirzepatide. CagriSema achieved approximately 23.0% weight loss versus 25.5% with tirzepatide — falling short of the trial's superiority endpoint by ~2.5 percentage points. While tirzepatide edged ahead, CagriSema's efficacy remains substantial and its distinct mechanism may matter for specific patient populations.

Side Effects and Safety Profile

CagriSema's safety profile aligns with the GLP-1 drug class — predominantly gastrointestinal effects, mild to moderate in most cases, and diminishing over time.

Most Common Adverse Events

• Nausea — most common, primarily during dose escalation
• Vomiting — higher rate than with semaglutide monotherapy; a key difference
• Diarrhea — common but typically transient
• Constipation — occasional, consistent with slowed gastric emptying
• Injection site reactions — mild and infrequent

Class Warnings (Applicable to All GLP-1 Agents)

• Medullary thyroid carcinoma (contraindicated in patients with personal/family history or MEN2)
• Acute pancreatitis
• Gallbladder disease (cholelithiasis)
• Diabetic retinopathy complications (in patients with pre-existing retinopathy)

No new safety signals beyond known GLP-1 and amylin class effects were identified in the REDEFINE trials. Serious adverse events were infrequent and not dose-dependent.

CagriSema vs. Semaglutide vs. Tirzepatide: A Practical Comparison

For clinicians and patients choosing between available and emerging therapies, the differences break down as follows:

• CagriSema vs. Semaglutide: CagriSema delivers roughly 7 additional percentage points of weight loss in non-diabetic patients (~23% vs ~16%). The additional amylin component drives this gap. Patients who have had suboptimal results on Wegovy may benefit from the switch.
• CagriSema vs. Tirzepatide: Very close in efficacy (~23% vs ~25.5%), with different mechanisms. Tirzepatide activates both GLP-1 and GIP receptors; CagriSema activates GLP-1 and amylin receptors. This distinction could be clinically meaningful for patients with specific metabolic profiles or side effect patterns.
• Administration: All three are once-weekly subcutaneous injections.
• Approval status: Semaglutide (Wegovy) and tirzepatide (Zepbound) are FDA-approved. CagriSema's NDA is under FDA review as of early 2026.

FDA Approval Timeline and Regulatory Status

Novo Nordisk submitted the NDA for CagriSema to the FDA on December 18, 2025 — the first-ever application for a GLP-1/amylin combination product. The application is for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.

FDA review is expected to complete in 2026. Standard review timelines for novel obesity drugs run 10–12 months from submission, though priority review could accelerate this. A European Medicines Agency application is also anticipated.

The brand name for CagriSema has not been officially confirmed at time of writing.

A Note on Compounding: What Patients Should Know

As GLP-1 shortages have driven interest in compounded semaglutide and tirzepatide, some patients may wonder whether compounded cagrilintide or CagriSema could be obtained through similar channels.

The answer is no — for important safety reasons:

• Cagrilintide is not an FDA-approved drug in any form. Compounding pharmacies may only compound drugs containing FDA-approved active pharmaceutical ingredients or those on specific shortage lists.
• CagriSema as a combination product has no approved status, and compounding an unapproved novel combination carries significant legal and safety risks.
• Online sources advertising "research-grade cagrilintide" operate outside pharmaceutical regulatory standards. Purity, potency, and safety cannot be assured.

The appropriate path to CagriSema access — once approved — is through licensed prescribers and accredited pharmacies.

What Comes Next: The CagriSema Pipeline

Novo Nordisk and the broader research community are exploring several extensions of this dual mechanism:

• Cardiovascular outcomes trial: Semaglutide (SELECT trial) demonstrated a 20% reduction in cardiovascular events. Whether CagriSema's superior weight loss translates into even greater CV benefit is under investigation.
• MASH (metabolic dysfunction-associated steatohepatitis): GLP-1 agents have shown liver-protective effects; the amylin component may add synergistic benefit in fatty liver disease.
• Long-term weight maintenance: Data beyond 68 weeks are needed, particularly around weight regain after discontinuation — a known limitation of all current obesity pharmacotherapies.
• Oral formulation research: Given Novo Nordisk's success with oral semaglutide (Rybelsus), oral delivery of an amylin analogue is an area of active investigation.

Conclusion

CagriSema is a genuinely novel pharmacological advance — not simply a higher-dose iteration of an existing drug, but a new class combining GLP-1 and amylin mechanisms in a single once-weekly injection. Phase 3 data from the REDEFINE trials demonstrate consistent 20%+ weight loss, meaningful glycemic improvements in type 2 diabetes, and a manageable safety profile.

While tirzepatide holds a slight edge in direct comparison, CagriSema offers a mechanistically distinct option that could become the preferred choice for millions of patients — particularly those with suboptimal GLP-1 monotherapy responses or those seeking a different side effect profile.

With Novo Nordisk's NDA under FDA review in 2026, CagriSema's approval could mark the next major milestone in the GLP-1 revolution. For anyone following the cutting edge of metabolic medicine, it is a development worth watching closely.

Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making any treatment decisions.